Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION In a mid-size sponsor after a complete response letter, an inspector asking for batch records you cannot produce this week put 505(b)(2) literature-to-product bridge table in play. Regulatory-affairs lead should decide whether the 505(b)(2) bridge is legally and scientifically enough without filling gaps 505(b)(2) literature-to-product bridge table does not contain.

DECISION Regulatory-affairs lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week.

HYPOTHESES TO TEST 1. Regulatory-affairs lead can defend Proceed under protocol from 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week in a Pharma & Life Sciences challenge. 2. Regulatory-affairs lead cannot defend Proceed under protocol from 505(b)(2) literature-to-product bridge table; Pause the pathway is what the extract actually supports after an inspector asking for batch records you cannot produce this week. 3. An inspector asking for batch records you cannot produce this week never reached the population in 505(b)(2) literature-to-product bridge table — reopen intake, do not close the 505(b)(2) bridge is. 4. Two facts in 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week conflict for regulatory-affairs lead; hold this FDA Response and Labeling file.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on the 505(b)(2) bridge is. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read 505(b)(2) literature-to-product bridge table against an inspector asking for batch records you cannot produce this week and write the one fact that would move the 505(b)(2) bridge is for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week). The follow-on FDA Response and Labeling action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the 505(b)(2) bridge is, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for regulatory-affairs lead - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - Missing page in 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week, if any - Regulatory or exam hook FDA Response and Labeling would cite